Form 4: Revolution Medicines General Counsel Sells Shares to Cover Tax Obligations

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,458 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 17, 2025, Jeff Cislini, the General Counsel of Revolution Medicines, sold 1,458 shares of common stock.
• The sale was executed at a price of $39.0403 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following the transaction, Cislini beneficially owns 59,764 shares, including 54,195 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction for tax purposes under a pre-existing plan, not indicative of a change in the executive's confidence in the company.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to tax obligations or diversification strategies. The use of a 10b5-1 plan indicates that the sale was pre-planned and not based on any inside information.

Comparison to Industry Standards

• Similar sales by executives at comparable biotech companies like Amgen, Gilead, and Vertex are routinely disclosed via Form 4 filings.
• The use of 10b5-1 plans is a standard practice among public company executives to avoid accusations of insider trading.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders, as it is a small percentage of the total outstanding shares and was conducted under a pre-arranged trading plan.

Key Dates

Keywords

Revolution Medicines, RVMD, Jeff Cislini, General Counsel, Form 4, SEC Filing, Stock Sale, Rule 10b5-1, Restricted Stock Units, RSUs, Tax Withholding